Lenovo Chairman and CEO, Yuanqing Yang, to Keynote CES 2026 at Sphere
ARLINGTON, Va., Aug. 6, 2025 /PRNewswire/ -- The Consumer Technology Association (CTA)® announces Yuanqing Yang, Chairman and CEO, Lenovo as a keynote speaker at CES® 2026. Lenovo will take its flagship event, Tech World, to CES, where global business gets done. Having Lenovo Tech World at CES puts decision-makers, partners, and media all in one place. For the past decade, Tech World has been Lenovo's platform to unveil new technologies, products, and solutions.
The event at Sphere, which will showcase content created exclusively for Lenovo by Sphere Studios, Sphere's in-house immersive content studio, marks the second consecutive year that a CES keynote will be delivered at the cutting-edge venue. Tech World comes as Lenovo and Sphere enter a multi-year global partnership, making Lenovo An Official Technology Partner of Sphere Studios.
Tech World @ CES will explore how Lenovo is defining the future through the fusion of AI, devices, infrastructure, and services. As a global technology partner for both Formula 1® and the FIFA World Cup 26™, the audience will see not only how Lenovo innovation will help individuals and businesses, but also how the company plans to use AI and its full portfolio of technologies to change the game for sports fans in the years to come.
"Over the past decade, Tech World has become Lenovo's key platform to reveal our vision, showcase our innovation, and launch our most exciting products, solutions, and partnerships," said Yuanqing Yang, Chairman and CEO, Lenovo. "Now, set against the backdrop of CES 2026, we'll give the audience an exclusive look at how our technology has revolutionized F1, unveil our plans for the first-ever AI-powered FIFA World Cup next summer, and create a hyper-personalized agent-native experience for individuals while unleashing Lenovo Hybrid AI Advantage for enterprise customers. Sphere is the perfect match for Lenovo in Las Vegas, where we will celebrate and share our commitment to delivering smarter AI for all by constantly redefining how technology can engage, inspire, and empower."
Under Yang's leadership, Lenovo has grown from the world's #1 PC manufacturer to a US$69 billion global technology powerhouse serving millions of customers every day in 180 markets and manufacturing in 11 markets across five continents. Yang is passionate about tech advancing broader societal progress, not just business growth. He is the recipient of many awards and industry accolades, including Barron's Best CEOs and the Edison Achievement Award.
"We're thrilled to welcome Lenovo and Yuanqing Yang to the CES keynote stage. CES is where innovators show up, and I look forward to seeing his vision for the technology solving big global challenges come to life at the incredible Sphere," said Gary Shapiro, CEO and Vice Chair, CTA.
As a Fortune Global 500 technology company, Lenovo rethinks the way organizations use hybrid AI to evolve their business. The keynote at Sphere will offer a unique experience that presents Lenovo's story in innovative ways.
"As a venue at the forefront of innovation, Sphere is a powerful platform for visionary brands looking to create transformative events and experiences," said Jennifer Koester, President and COO, Sphere. "We are honored to collaborate with Lenovo not only to help bring their vision to life during this CES Keynote, but also as part of our broader partnership that will leverage Lenovo technology to deliver immersive experiences across all Sphere events."
At CES 2025, Delta used Sphere's immersive capabilities, including its haptic seats, to create a multi-sensory experience for over 8000 attendees.
"Having the first ever CES keynote at Sphere was a huge highlight of our 2025 show," said Kinsey Fabrizio, President, CTA. "We look forward to experiencing how Lenovo will use Sphere to showcase how tech powers all industries."
Don't miss the opportunity to experience a CES keynote in Sphere — an event that will demonstrate how Lenovo is driving progress and reimagining our digital future. The keynote is at 5:00 PM PT on Tuesday, January 6. Information on ticketing and logistics will be available soon.
This event is only open to credentialed CES attendees. Sign up for alerts about CES 2026 registration, opening this fall.
About CES®:
CES is the most powerful tech event in the world – the proving ground for breakthrough technologies and global innovators. This is where the world's biggest brands do business and meet new partners, and the sharpest innovators hit the stage. Owned and produced by the Consumer Technology Association (CTA)®, CES features every aspect of the tech sector. CES 2026 takes place Jan. 6-9 in Las Vegas. Learn more at CES.tech and follow CES on social.
About Consumer Technology Association (CTA)®:
As North America's largest technology trade association, CTA is the tech sector. Our members are the world's leading innovators – from startups to global brands – helping support more than 18 million American jobs. CTA owns and produces CES® – the most powerful tech event in the world. Find us at CTA.tech. Follow us @CTAtech.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
17 hours ago
- Korea Herald
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of AVTOZMA ® (tocilizumab-anoh) to include the treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged 2 years and older. Following FDA approval of the additional indication for CRS, AVTOZMA IV now aligns with all indications approved for ACTEMRA ® IV in the United States. [1] Earlier this year, the FDA approved AVTOZMA as a biosimilar to ACTEMRA in IV formulations for the treatment of multiple diseases including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19). [1] CRS is a potentially life-threatening condition that occurs when the immune system is highly activated, leading to the rapid and excessive release of cytokines into the bloodstream. During a cytokine storm, the overactivated immune system can cause widespread inflammation and damage to healthy tissue and organs throughout the body with symptoms ranging from mild, flu-like symptoms to more severe complications such as low blood pressure, difficulty breathing, and multi-organ failure. [2] "We are proud that AVTOZMA IV has now achieved full indication alignment with the reference ACTEMRA IV. This milestone marks an important step forward in our mission to deliver a safe and effective therapy for CRS," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "This FDA approval expands access to high-quality biologics and supports beneficial patient outcomes across multiple therapeutic areas." In accordance with the patent settlement agreement with Genentech, the IV formulation of AVTOZMA is expected to be available in the U.S. on August 31, 2025. Celltrion holds a license to market the subcutaneous formulation in the U.S. commencing on the licensed launch date, which remains confidential. Notes to Editors: AVTOZMA ® (tocilizumab-anoh), containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab. AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and European Commission (EC) in January and February 2025, respectively. INDICATION AVTOZMA ® (tocilizumab-anoh) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS INFECTIONS AVTOZMA ® and other tocilizumab products may increase the risk of serious infections, potentially leading to hospitalization or death, especially in patients using concurrent immunosuppressants. If a serious infection develops, interrupt AVTOZMA until the infection is controlled. Reported infections include: Monitor patients for signs of infection, including TB, during and after AVTOZMA treatment. Contraindications: Known hypersensitivity to tocilizumab products. Serious Infections. Serious and sometimes fatal infections have been reported with AVTOZMA. Do not use during active infections, including localized infections. Discontinue AVTOZMA if a serious infection occurs and resume only once controlled. Gastrointestinal (GI) Perforation. Gastrointestinal perforations, often linked to diverticulitis, have been reported with tocilizumab. Use AVTOZMA cautiously in high-risk patients and promptly evaluate new abdominal symptoms for early detection and management. Hepatoxicity. Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop. Changes in Laboratory Parameters. Monitor neutrophils, platelets, liver enzymes, and lipids due to potential treatment-related changes; avoid initiating AVTOZMA in patients with critically low ANC or platelet counts. Immunosuppression. The impact of AVTOZMA on malignancy development is unknown, but it may increase risk as an immunosuppressant. Hypersensitivity Reactions, including anaphylaxis, and death, have occurred; administer IV infusions with anaphylaxis management support, discontinue permanently if reactions occur, and avoid use in patients with known hypersensitivity. Demyelinating Disorders. The impact of tocilizumab on demyelinating disorders is unknown, but rare cases were reported; monitor symptoms and use caution with preexisting or recent disorders. Active Hepatic Disease and Hepatic Impairment. Treatment with AVTOZMA is not recommended. Live Vaccines. Avoid concurrent use with AVTOZMA. Adverse Reactions (≥5%) include upper respiratory tract infections, nasopharyngitis, headache, hypertension, elevated ALT, and injection site reactions. About Celltrion Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion endeavors to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 countries. Celltrion has seven biosimilars approved by the U.S. FDA: INFLECTRA ® (infliximab-dyyb), TRUXIMA ® (rituximab-abbs), HERZUMA ® (trastuzumab-pkrb), VEGZELMA ® (bevacizumab-adcd), YUFLYMA ® (adalimumab-aaty), STEQEYMA ® (ustekinumab-stba), and AVTOZMA ® (tocilizumab-anoh), as well as novel biologic ZYMFENTRA ® (infliximab-dyyb). For more information, please visit Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", "anticipates", the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws.
Korea Herald
a day ago
- Korea Herald
Lenovo Chairman and CEO, Yuanqing Yang, to Keynote CES 2026 at Sphere
Lenovo brings Tech World to CES 2026 with the theme "Smarter AI for All" ARLINGTON, Va., Aug. 6, 2025 /PRNewswire/ -- The Consumer Technology Association (CTA)® announces Yuanqing Yang, Chairman and CEO, Lenovo as a keynote speaker at CES® 2026. Lenovo will take its flagship event, Tech World, to CES, where global business gets done. Having Lenovo Tech World at CES puts decision-makers, partners, and media all in one place. For the past decade, Tech World has been Lenovo's platform to unveil new technologies, products, and solutions. The event at Sphere, which will showcase content created exclusively for Lenovo by Sphere Studios, Sphere's in-house immersive content studio, marks the second consecutive year that a CES keynote will be delivered at the cutting-edge venue. Tech World comes as Lenovo and Sphere enter a multi-year global partnership, making Lenovo An Official Technology Partner of Sphere Studios. Tech World @ CES will explore how Lenovo is defining the future through the fusion of AI, devices, infrastructure, and services. As a global technology partner for both Formula 1® and the FIFA World Cup 26™, the audience will see not only how Lenovo innovation will help individuals and businesses, but also how the company plans to use AI and its full portfolio of technologies to change the game for sports fans in the years to come. "Over the past decade, Tech World has become Lenovo's key platform to reveal our vision, showcase our innovation, and launch our most exciting products, solutions, and partnerships," said Yuanqing Yang, Chairman and CEO, Lenovo. "Now, set against the backdrop of CES 2026, we'll give the audience an exclusive look at how our technology has revolutionized F1, unveil our plans for the first-ever AI-powered FIFA World Cup next summer, and create a hyper-personalized agent-native experience for individuals while unleashing Lenovo Hybrid AI Advantage for enterprise customers. Sphere is the perfect match for Lenovo in Las Vegas, where we will celebrate and share our commitment to delivering smarter AI for all by constantly redefining how technology can engage, inspire, and empower." Under Yang's leadership, Lenovo has grown from the world's #1 PC manufacturer to a US$69 billion global technology powerhouse serving millions of customers every day in 180 markets and manufacturing in 11 markets across five continents. Yang is passionate about tech advancing broader societal progress, not just business growth. He is the recipient of many awards and industry accolades, including Barron's Best CEOs and the Edison Achievement Award. "We're thrilled to welcome Lenovo and Yuanqing Yang to the CES keynote stage. CES is where innovators show up, and I look forward to seeing his vision for the technology solving big global challenges come to life at the incredible Sphere," said Gary Shapiro, CEO and Vice Chair, CTA. As a Fortune Global 500 technology company, Lenovo rethinks the way organizations use hybrid AI to evolve their business. The keynote at Sphere will offer a unique experience that presents Lenovo's story in innovative ways. "As a venue at the forefront of innovation, Sphere is a powerful platform for visionary brands looking to create transformative events and experiences," said Jennifer Koester, President and COO, Sphere. "We are honored to collaborate with Lenovo not only to help bring their vision to life during this CES Keynote, but also as part of our broader partnership that will leverage Lenovo technology to deliver immersive experiences across all Sphere events." At CES 2025, Delta used Sphere's immersive capabilities, including its haptic seats, to create a multi-sensory experience for over 8000 attendees. "Having the first ever CES keynote at Sphere was a huge highlight of our 2025 show," said Kinsey Fabrizio, President, CTA. "We look forward to experiencing how Lenovo will use Sphere to showcase how tech powers all industries." Don't miss the opportunity to experience a CES keynote in Sphere — an event that will demonstrate how Lenovo is driving progress and reimagining our digital future. The keynote is at 5:00 PM PT on Tuesday, January 6. Information on ticketing and logistics will be available soon. This event is only open to credentialed CES attendees. Sign up for alerts about CES 2026 registration, opening this fall. About CES®: CES is the most powerful tech event in the world – the proving ground for breakthrough technologies and global innovators. This is where the world's biggest brands do business and meet new partners, and the sharpest innovators hit the stage. Owned and produced by the Consumer Technology Association (CTA)®, CES features every aspect of the tech sector. CES 2026 takes place Jan. 6-9 in Las Vegas. Learn more at and follow CES on social. About Consumer Technology Association (CTA)®: As North America's largest technology trade association, CTA is the tech sector. Our members are the world's leading innovators – from startups to global brands – helping support more than 18 million American jobs. CTA owns and produces CES® – the most powerful tech event in the world. Find us at Follow us @CTAtech.
Korea Herald
a day ago
- Korea Herald
American Express and Marriott International Launch Enhanced Co-Brand Credit Cards in Japan With New Premium Experiences
® American Express ® Premium Card and Marriott Bonvoy ® American Express ® Card enhance travel experience with everyday spend ing TOKYO, Aug. 6, 2025 /PRNewswire/ -- Today, American Express and Marriott International announced their enhanced co-brand credit cards in Japan. The Marriott Bonvoy ® American Express ® Premium Card and the Marriott Bonvoy ® American Express ® Card have been enhanced with exclusive benefits, exclusive experiences and premium access. The new version of both cards will be available nationwide, with applications opening on Thursday, August 21, 2025. The refreshed co-brand cards are designed to cater to the evolving preferences of not only avid travelers, but also those seeking elevated experience in everyday moments. Through Marriott Bonvoy ®, Marriott International's award-winning loyalty program, Card Members can earn more points on both daily purchases and stays at participating hotels. Card Members also receive a complimentary night's stay at Marriott International hotels and resorts worldwide and can qualify for elite membership status—such as Gold Elite or Platinum Elite—upon meeting spend conditions. This elite status in turn unlocks access to exclusive benefits, including room upgrades, late check-outs, and more. Key Benefits of the New Co-Brand Cards Benefits for the new Marriott Bonvoy ® American Express ® Premium Card include *: Benefits for the new Marriott Bonvoy ® American Express ® Card include *: American Express International, Inc. and Marriott International will be also providing a limited time offer for successful applications received between August 21 and October 21, 2025. In addition to the standard Marriott Bonvoy points welcome offer, a new Marriott Bonvoy ® American Express ® Premium Card Member can receive up to 45,000 Marriott Bonvoy Points, and a new Marriott Bonvoy ® American Express ® Card Member can receive up to 30,000 Marriott Bonvoy Points during the period. "The Marriott Bonvoy American Express Co-brand Cards have been very well received by customers, especially among those who love spending time in premium hotels," said Naomi Mizumura, Vice President, International Card Services, American Express Japan. "In line with our long-standing partnership with Marriott International, we have refreshed the offering to reflect the recent increase in demand for premium hotels and to offer an even higher quality hotel stay experience to our existing customers. In addition to the value offered by the Marriott Bonvoy program, as a premium lifestyle brand, American Express continues to deliver its vision of world's best customer experience to an even wider audience. "Marriott Bonvoy remains committed to being a trusted and beloved brand for our customers in Japan, and we always strive to create deeper connections with them by continually innovating our offerings and delivering world-class hospitality. By combining the global reach of Marriott Bonvoy, our extensive brand portfolio and a wealth of exclusive member benefits, we are confident in our ability to deliver a more personalized, memorable and elevated experience for our cardmembers," said Ramesh Daryanani, Vice President of Global Sales, Loyalty Operations & Partnerships, Asia Pacific excluding China, Marriott International. As Japanese travelers resume travel both at home and abroad, the enhanced cards offer a timely, exciting way for customers to earn rewards and enjoy greater value from every spend. According to the latest survey by Marriott, 72% of affluent travelers in Asia Pacific, excluding China, intend to increase their spending on luxury travel in the next 12 months. Trust in luxury hotel brands is also on the rise, as travelers look for consistency, select experiences, and higher standards of service. *Overview of Full Benefits for New Cards About American Express American Express (NYSE: AXP) is a global payments and premium lifestyle brand powered by technology. Our colleagues around the world back our customers with differentiated products, services and experiences that enrich lives and build business success. Founded in 1850 and headquartered in New York, American Express' brand is built on trust, security, and service, and a rich history of delivering innovation and Membership value for our customers. With over a hundred million merchant locations across our global network, we seek to provide the world's best customer experience every day to a broad range of consumers, small and medium-sized businesses, and large corporations. For more information about American Express, visit and About Marriott Bonvoy Marriott Bonvoy, Marriott International's portfolio of more than 30 hotel brands and 10,000 global destinations, offers renowned hospitality in the most memorable locations around the world. The award-winning travel program and marketplace gives members access to transformative, eye-opening experiences around the corner and across the globe. To enroll for free or for more information about Marriott Bonvoy, visit To download the Marriott app, go here. Travelers can also connect with Marriott Bonvoy on Facebook, X, Instagram, and TikTok. Marriott International, Inc. (Nasdaq: MAR) is based in Bethesda, Maryland, USA, and encompasses a portfolio of nearly 9,500 properties across more than 30 leading brands in 144 countries and territories. Marriott operates, franchises, and licenses hotel, residential, timeshare, and other lodging properties all around the world. The company offers Marriott Bonvoy ®, its highly awarded travel platform. For more information, please visit our website at and for the latest company news, visit In addition, connect with us on Facebook and @MarriottIntl on X and Instagram. Marriott encourages investors, the media, and others interested in the company to review and subscribe to the information Marriott posts on its investor relations website at or Marriott's news center website at which may be material. The contents of these websites are not incorporated by reference into this press release or any report or document Marriott files with the U.S. Securities and Exchange Commission, and any references to the websites are intended to be inactive textual references only.
